According to a meta-analysis of 351 phase I trials, choosing a therapy based on the abnormalities that drive a tumor yields higher response rates than therapeutic selections that aren't biomarker-driven.
from Cancer via ola Kala on Inoreader http://ift.tt/2aee8Uu
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου